Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Interventions

DRUG

NBI-98854 50 mg capsule

Trial Locations (3)

Orlando Clinical Research Center, Orlando

Davita Clinical Research, Minneapolis

DaVita Clinical Research, Lakewood